Patents by Inventor Otto Schwarz
Otto Schwarz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5410022Abstract: The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:a) chromatographic purification of a factor VIII-containing fraction,b) tenside treatment of factor VIII in an aqueous solution at a tenside/protein ratio of from 1:1 to 1000:1, andc) heat treatment of the factor VIII preparation in the solid state.Type: GrantFiled: April 20, 1993Date of Patent: April 25, 1995Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Friedrich Elsinger, Herbert Gritsch, Yendra Linnau, Otto Schwarz, Peter Turecek, Gunther Wober
-
Patent number: 5234685Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.Type: GrantFiled: September 26, 1989Date of Patent: August 10, 1993Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Johann Eibl, Yendra Linnau, Otto Schwarz
-
Patent number: 5122373Abstract: An immunoglobulin-G-containing fraction from human or animal plasma comprising monomeric IgG molecules as well as at least 70% gammaglobulins, destined for intravenous application.The fraction has a low anticomplementary activity and is substantially free of vasoactive and leucopenically active as well as bronchospastic substances.Type: GrantFiled: August 20, 1990Date of Patent: June 16, 1992Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Yendra Linnau, Otto Schwarz
-
Patent number: 4904641Abstract: There is disclosed a method of inactivating reproducible filterable pathogens in blood plasma products by applying elevated temperatures. The blood plasma products are heat treated in a solid state in a closed inactivation container in the presence of specific amounts of water and organic compounds, provided that the water substantially remains physically bound to the blood plasma products, while the organic compound is present in a gaseous form in the atmosphere. The water content of the blood plasma products is 0.08 to 0.40. The concentration of the organic compounds in the gaseous phase is 0.01 to 10 g per liter of container volume.Type: GrantFiled: January 3, 1989Date of Patent: February 27, 1990Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Johann Eibl, Otto Schwarz, Fritz Elsinger, Gunter Wober, Anton Philapitsch, Yendra Linnau, Friedrich Dorner, Karl Trambauer, Wolfgang Frechinger
-
Patent number: 4886758Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.Type: GrantFiled: September 15, 1986Date of Patent: December 12, 1989Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Johann Eibl, Yendra Linnau, Otto Schwarz
-
Patent number: 4814435Abstract: There is disclosed a method of producing a Factor VIII (AHF) containing fraction having a specific activity of at least 2.5 units of Factor VIII/mg protein as well as a portion of immunoglobulin G (IgG) of 10 mg/1000 units of Factor VIII at the most. Its risk of transmission of viral or bacterial infections is to be avoided or largely reduced. The method consists in that undesired proteins are at first precipitated from a Factor VIII (AHF) containing plasma fraction in the presence of SPS. The purified Factor VIII containing solution is treated with suitable salts or salt mixtures in order to obtain a Factor VIII containing precipitate. This precipitate is dissolved, lyophilized and finally heat-treated.Type: GrantFiled: October 15, 1987Date of Patent: March 21, 1989Assignee: Immuno Aktiengesellschaft fur chemisch-medizinisch ProdukteInventors: Otto Schwarz, Yendra Linnau
-
Patent number: 4687664Abstract: There is described a method of inactivating reproducible pathogens in preparations containing plasmatic enzymes and proenzymes, activated or non-activated coagulation factors, such as Factors II, V, VII, VIII, IX, X, XIII, "FEIBA", prothrombin complex preparations, plasmatic inhibitors, immunoglobulins or other blood products, such as fibronectin and fibrinogen. In order to break and overcome the protective effect of proteins on pathogens by simultaneously preserving the biological activity and the molecular integrity of the proteins, the preparation is adjusted to a salt concentration of more than 0.5 molar by the addition of ammonium sulfate and is thermally treated, whereupon the ammonium sulfate is removed from the preparation.Type: GrantFiled: April 30, 1984Date of Patent: August 18, 1987Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Anton Philapitsch, Gunter Wober, Johann Eibl, Otto Schwarz
-
Patent number: 4640834Abstract: A method of inactivating viruses in blood products is described, wherein the blood products are heat-treated in a humid or in a solid state in the presence of inorganic or organic hydroxyl group-containing compounds having an H.sup.+ -dissociation constant of <10.sup.-11 in a concentration of more than 0.05 (5% by weight) and less than 0.70 (70% by weight). The hydroxyl group-containing compounds may be water, methanol, ethanol or mannitol. The temperature may amount up to 121.degree. C., the heat treatment may last from 1 s to 100 h. The inactivation method may be applied for producing blood products selected from enzymes, proenzymes including coagulation factors, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin or plasma, the inactivation destroying any reproducible filterable pathogens that might be present.Type: GrantFiled: February 26, 1985Date of Patent: February 3, 1987Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Johann Eibl, Otto Schwarz, Fritz Elsinger, Gunter Wober, Anton Philapitsch, Yendra Linnau, Friedrich Dorner, Karl Trambauer, Wolfgang Frechinger
-
Patent number: 4522751Abstract: There is described a method for producing a preparation having a high content of Factor VIII (AHF), i.e. with a specific activity of at least 1.5 units of Factor VIII/mg protein, immunoglobulin G (IgG) of from 15 to 30 mg/1000 units of Factor VIII and fibrinogen of from 20 to 40 mg/100 units of Factor VIII. The method consists in that a Factor VIII containing plasma fraction is dissolved in a buffer, the solution is purified from undesired proteins by precipitation and is concentrated, the precipitation of undesired proteins being carried out in the presence of sulfated polysaccharide at a pH of from 6 to 7. After separation of the undesired proteins, a Factor VIII concentrate is precipitated, dissolved and processed into stable form. If desired, an antithrombin III-heparin complex or an antithrombin III-heparinoid complex is added to the solution.Type: GrantFiled: May 18, 1984Date of Patent: June 11, 1985Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Yendra Linnau, Otto Schwarz
-
Patent number: 4414976Abstract: A tissue adhesive on the basis of human or animal protein contains factor XIII and at least 33% by weight of fibrinogen, has a ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, of at least 80, contains fibrinogen and albumin in the total protein at a ratio of 33 to 90:5 to 40, contains plasminogen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen and has been lyophilized.Type: GrantFiled: September 13, 1982Date of Patent: November 15, 1983Assignee: Immuno Aktiengesellschaft fur chemischmedizinische ProdukteInventors: Otto Schwarz, Yendra Linnau, Franz Loblich, Thomas Seelich
-
Patent number: 4404131Abstract: In a method of producing a factor-VIII(AHF)-high-concentrate having a specific activity of at least 2.5 units AHF and a fibrinogen content of less than 0.25 mg/mg protein from human or animal plasma, the plasma is subjected to a multi-step fractionation. The fraction purified by these fractionation measures and enriched in factor VIII (AHF) is subjected to a cryoalcohol precipitation and the resulting precipitate is processed into a stable form.Type: GrantFiled: July 29, 1981Date of Patent: September 13, 1983Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Otto Schwarz, Yendra Linnau
-
Patent number: 4395396Abstract: In a method of producing a blood-coagulation-promoting preparation based on human proteins and having a content of coagulation factors II, VII, IX and X and factor-VIII-inhibitor-bypassing-activity (FEIBA), human plasma is treated with sulphated high-polymer carbohydrates and/or with basic ion exchangers, the protein mixture with generated FEIB-activity is adsorbed on the ion exchanger, and the preparation is gained by elution and concentration.Type: GrantFiled: July 14, 1981Date of Patent: July 26, 1983Assignee: Immuno Aktiengesellschaft fur Chemisch-medizinische ProdukteInventors: Johann Eibl, Otto Schwarz, Fritz Elsinger, Anton Philapitsch
-
Patent number: 4377572Abstract: This invention relates to a tissue adhesive used in mammals for among other things to connect tissue or organs, in sealing wounds, stopping bleeding and healing wounds. The adhesive comprises specified amounts of factor XIII, fibrinogen, cold-insoluble globulin and albumin and plasminogen-activator inhibitor or plasmin inhibitor.Type: GrantFiled: July 7, 1981Date of Patent: March 22, 1983Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Otto Schwarz, Yendra Linnau, Franz Loblich, Thomas Seelich
-
Patent number: 4362567Abstract: A tissue adhesive on the basis of human or animal protein contains factor XIII and at least 33% by weight of fibrinogen, has a ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, of at least 80, contains fibrinogen and albumin in the total protein at a ratio of 33 to 90:5 to 40, contains plasminogen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen and has been lyophilized.Type: GrantFiled: February 4, 1980Date of Patent: December 7, 1982Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Otto Schwarz, Yendra Linnau, Franz Loblich, Thomas Seelich
-
Patent number: 4298598Abstract: A tissue adhesive on the basis of human or animal proteins has a content of factor XIII and fibrinogen, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounting to at least 80. Furthermore, it contains a plasminogen-activator-inhibitor or plasmin-inhibitor in an amount of 20 to 2,000 KIU per ml.Type: GrantFiled: February 4, 1980Date of Patent: November 3, 1981Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Otto Schwarz, Yendra Linnau, Franz Loblich, Thomas Seelich
-
Patent number: 4276283Abstract: A method of preparing an intravenously administrable immune globulin preparation containing antibodies, in which human blood plasma is fractionated and an immune-globulin-containing fraction is freed from undesired protein impurities by a single or repeated precipitation with polyethylene glycol, is characterized in that the immune-globulin-containing fraction is subjected in a first purification step prior to the polyethylene glycol precipitation to a treatment with an aqueous solution of a salt of an inorganic acid, and in that at least one of the following purification steps is carried out with polyethylene glycol in the presence of a soluble carbohydrate or a non-protein-precipitating polyol, whereupon the immune globulin freed from protein impurities is precipitated from the remaining solution by water-soluble polymers and is finished in a known manner to the pharmaceutical preparation.Type: GrantFiled: September 10, 1979Date of Patent: June 30, 1981Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Martha Eibl, Otto Schwarz, Yendra Linnau
-
Patent number: 4209120Abstract: An apparatus for the division-true, intermittent feed of a sheet of indeterminate length has a sheet supply roll; a table for receiving the sheet from the supply roll; a sheet tensioning device disposed between the supply roll and the table; an advancing device for advancing the sheet in each operational cycle through a forward feed stroke that is greater than the divisional distance defined by spaced markings on the sheet; a cutting device for cyclically severing a length from the sheet subsequent to the forward feed stroke; a reversing device for retracting the sheet in each operational cycle through a centering stroke subsequent to the forward feed stroke.Type: GrantFiled: October 26, 1978Date of Patent: June 24, 1980Assignee: SIG Schweizerische Industrie-GesellschaftInventors: Franz Ruegg, Otto Schwarz
-
Patent number: 4168577Abstract: The present invention refers to a device for stepwise displacement of a work-piece or a similar body, the device comprising a rod made from a reversibly expanding or compressing material coupled to an activation device whereby the rod has its ends resting in clamping brackets to be clamped alternatively at the expansion or compressing of the rod.Type: GrantFiled: April 5, 1977Date of Patent: September 25, 1979Assignee: LKB-Produkter ABInventors: Anton Soderkvist, Otto Schwarz
-
Patent number: 4160025Abstract: In a method of producing a blood-coagulation-promoting preparation from human blood plasma, which preparation contains a new blood-coagulating substance called "FEIBA", human plasma with citrate ions is treated with water-insoluble inorganic coagulation-physiologically-surface-active substances in the absence of free calcium ions, thus generating "FEIBA", the water-insoluble substances are separated, the supernatant is treated with basic ion exchangers, wherein "FEIBA" and the coagulation factors II-VII-IX-X adhere to the ion exchangers, and "FEIBA" and the factors II-VII-IX-X are eluted and concentrated.Type: GrantFiled: August 8, 1977Date of Patent: July 3, 1979Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Johann Eibl, Otto Schwarz, Fritz Elsinger